Mora Cuesta V, Solis Gomez B, Perez Rojo R
Open Respir Arch. 2025; 7(2):100398.
PMID: 40008074
PMC: 11850141.
DOI: 10.1016/j.opresp.2025.100398.
Gumber L, Jackson H, Gomez N, Hopkins G, Tucis D, Chakravorty M
Rheumatol Adv Pract. 2024; 7(3):rkad097.
PMID: 38515961
PMC: 10956718.
DOI: 10.1093/rap/rkad097.
Zhang Z, Huang J, Wang L, Pan Z, Huang J, Jiang C
Blood Sci. 2024; 6(2):e00183.
PMID: 38283406
PMC: 10817160.
DOI: 10.1097/BS9.0000000000000183.
Tomisti L, Angelotti F, Lenzi M, Amadori F, Sarteschi G, Porcu A
Life (Basel). 2023; 13(6).
PMID: 37374049
PMC: 10302885.
DOI: 10.3390/life13061266.
Mathews A, Paul A, Yu I, McGahan C, Bhang E, Villa D
Heliyon. 2022; 8(12):e12140.
PMID: 36506364
PMC: 9726656.
DOI: 10.1016/j.heliyon.2022.e12140.
COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature.
Armagan B, Eksin M, Guven S, Ozdemir B, Dagli P, Kucuksahin O
Turk J Med Sci. 2022; 52(4):899-909.
PMID: 36326380
PMC: 10387857.
DOI: 10.55730/1300-0144.5389.
Humoral and cellular immunity in patients with rare autoimmune rheumatic diseases following SARS-CoV-2 vaccination.
Gumber L, Gomez N, Hopkins G, Tucis D, Bartlett L, Ayling K
Rheumatology (Oxford). 2022; 62(6):2294-2303.
PMID: 36250898
PMC: 9619726.
DOI: 10.1093/rheumatology/keac574.
Association of Disease-Modifying Therapies with COVID-19 Susceptibility and Severity in Patients with Multiple Sclerosis: A Systematic Review and Network Meta-Analysis.
Barzegar M, Houshi S, Sadeghi E, Hashemi M, Pishgahi G, Bagherieh S
Mult Scler Int. 2022; 2022:9388813.
PMID: 36187599
PMC: 9519336.
DOI: 10.1155/2022/9388813.
Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.
Weisser M, Khanna N, Hedstueck A, Tschudin Sutter S, Roesch S, Stehle G
Transfusion. 2022; 62(10):1997-2011.
PMID: 36054476
PMC: 9538076.
DOI: 10.1111/trf.17083.
Clinical course of idiopathic inflammatory myopathies in COVID-19 pandemic: a single-center experience.
Apaydin H, Erden A, Guven S, Armagan B, Karakas O, Ozdemir B
Future Virol. 2022; .
PMID: 35747325
PMC: 9203034.
DOI: 10.2217/fvl-2021-0146.
Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway.
DAbramo A, Vita S, Maffongelli G, Beccacece A, Agrati C, Cimini E
Front Immunol. 2022; 13:911339.
PMID: 35711444
PMC: 9196078.
DOI: 10.3389/fimmu.2022.911339.
The Effect of Waning on Antibody Levels and Memory B Cell Recall following SARS-CoV-2 Infection or Vaccination.
Forgacs D, Silva-Moraes V, Sautto G, Hanley H, Gattiker J, Jefferson A
Vaccines (Basel). 2022; 10(5).
PMID: 35632452
PMC: 9143792.
DOI: 10.3390/vaccines10050696.
COVID-19-Associated Pneumonia in a B-Cell-Depleted Patient With Non-Hodgkin Lymphoma: Recovery With Hyperimmune Plasma.
Colombo D, Gatti A, Alabardi P, Bompane D, Bonardi G, Mumoli N
J Hematol. 2022; 11(2):77-80.
PMID: 35573753
PMC: 9076145.
DOI: 10.14740/jh845.
The effect of waning on antibody levels and memory B cell recall following SARS-CoV-2 infection or vaccination.
Forgacs D, Moraes V, Hanley H, Gattiker J, Jefferson A, Ross T
bioRxiv. 2022; .
PMID: 35313572
PMC: 8936119.
DOI: 10.1101/2022.03.16.484099.
Strategies Towards Antigen-Specific Treatments for Membranous Nephropathy.
Kollner S, Seifert L, Zahner G, Tomas N
Front Immunol. 2022; 13:822508.
PMID: 35185913
PMC: 8850405.
DOI: 10.3389/fimmu.2022.822508.
COVID-19 outcomes in persons with multiple sclerosis treated with rituximab.
Iyer R, S R, M J, R J
Mult Scler Relat Disord. 2022; 57:103371.
PMID: 35158435
PMC: 8579699.
DOI: 10.1016/j.msard.2021.103371.
Plasma exchange with COVID-19 convalescent plasma in a patient with severe ANCA-associated vasculitis and COVID-19 pneumonia after rituximab therapy.
Kochanek M, Garcia Borrega J, Beckmann L, Neuhann J, Gathof B, Di Cristanziano V
Clin Kidney J. 2022; 15(1):162-164.
PMID: 35028131
PMC: 8244539.
DOI: 10.1093/ckj/sfab095.
Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report.
Daher A, Muller T, Spiesshoefer J, Dreher M, Panse J
Respir Med Case Rep. 2021; 34:101560.
PMID: 34868871
PMC: 8628608.
DOI: 10.1016/j.rmcr.2021.101560.
Undetectable SARS-CoV-2 active adaptive immunity-post-vaccination or post-COVID-19 severe disease-after immunosuppressants use.
Adedoyin O, Brijmohan S, Lavine R, Lisung F
BMJ Case Rep. 2021; 14(11).
PMID: 34844968
PMC: 8634224.
DOI: 10.1136/bcr-2021-246308.
COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge.
Furlan A, Forner G, Cipriani L, Vian E, Rigoli R, Gherlinzoni F
Front Immunol. 2021; 12:763412.
PMID: 34804051
PMC: 8595333.
DOI: 10.3389/fimmu.2021.763412.
